LOS ANGELES, CA--(Marketwire - Feb 13, 2013) - Ritter Pharmaceuticals, Inc. today announced the appointment of Larry I. Good, M.D., F.A.C.G. to the position of Chief Medical Officer. Dr. Good's extensive experience as a practicing gastroenterologist has strengthened the company's mission to develop novel treatments for lactose intolerance and other gastrointestinal disorders. Ritter expects to design and initiate its next Phase 2 clinical studies of RP-G28 in patients with lactose intolerance (LI) later this year.
"Dr. Good's appointment to the lead research and development role at Ritter acknowledges his contributions to our R&D team to date, and will provide valuable expertise as we advance our clinical programs," said Andrew Ritter, president and chief executive officer of Ritter Pharmaceuticals.
"Ritter's approach to treating lactose intolerance and other GI disorders through colonic adaptation has the potential to change how these disorders are treated in the future," said Dr. Good. "I look forward to overseeing future R&D at Ritter, including advanced clinical study design and implementation," he added.
Larry Good, M.D.
Dr. Good is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. He joined Ritter Pharmaceuticals in 2012. Dr. Good is nationally recognized for his clinical experience with clostridium difficile and has conducted extensive clinical research in a range of GI specialties, including biliary lipid metabolism, irritable bowel syndrome and inflammatory bowel disease. Dr. Good received his M.D. from the Medical University of South Carolina and was Chief Resident in Medicine. He was a Fellow in Gastroenterology at the University of Pennsylvania. Dr. Good has publications in prestigious peer review journals including The New England Journal Of Medicine, Gastroenterology and the American Journal of Gastroenterology. He has been recognized by Who's Who in Medicine and Science, has been selected as one of America's Top Gastroenterologists by the Consumers' Research Council of America and has received the Golden Apple Award for excellence in medical teaching by the American Medical Student Association.
Lactose Intolerance is a common condition attributed to insufficient levels of the enzyme lactase which is needed to properly digest lactose, a complex sugar found in milk and milk containing foods. People with lactose intolerance who ingest lactose-containing foods may experience pain and other symptoms which may limit their diet and cause embarrassment. The condition is prevalent worldwide, where it is estimated that more than 1 billion people may be lactose intolerant. To date, no medical treatment is available to help those who suffer with this condition.
Ritter Pharmaceuticals (www.ritterpharmaceuticals.com)
Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem. Ritter is rapidly establishing itself as the world's leader in lactose intolerance research and development. Ritter's RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance, and may well be the first medical option available to LI patients some day.